Insights

New Targets to Improve Patient Outcomes in MZL and FL

Exploring Immunotherapy Combinations in Endometrial Cancer

Inside the Clinic: Graft-versus-Host Disease Best Practices

MET Exon 14 Skipping Mutations in Non–Small Cell Lung Cancer

Graft Versus Host Disease

Combinations are the Future in FLT3-Mutated AML

Improving Management of Relapsed/Refractory Multiple Myeloma

Recent Developments in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

The Impact of Chemotherapy-Induced Myelosuppression

Key Advances in Endometrial Cancer

Modern Perspectives in Advanced Melanoma

Emerging Strategies for Renal Cell Carcinoma

Treatment Options in Chronic Lymphocytic Leukemia: A Global Perspective 

Individualizing Treatment Approaches in MPN 

Targeting KRAS Mutations: A Novel Approach in Advanced NSCLC

Treatment Options in Metastatic Renal Cell Carcinoma

First Results of the Phase 3 CheckMate 9ER Trial

Considerations of Adjuvant Therapy in EGFR+ ES-NSCLC

2021: The Year of Advances in Unresectable HCC?

Optimizing Treatment Strategies in Relapsed/Refractory Metastatic CRC

Improving Survival in Metastatic Urothelial Cancer

Major Advances in RET Inhibition for NSCLC and MTC

EGFR-Mutated NSCLC: Are Frontline Combinations the Future?

Academic Focus: CAR-T Therapy for Relapsed/Refractory NHL

Inside the Clinic: Acute Graft-versus-Host Disease 

Treating Adult Acute Lymphocytic Leukemia in 2016

ADT and the Risk of Major Adverse Cardiovascular Events

Checkpoint Inhibitors in Advanced Bladder Cancer

Clinical Management of Advanced Colorectal Cancer

Updates in Advanced Gastric/GEJ Cancer Treatment

Expanding Role of PARP Inhibitors in Advanced Ovarian Cancer

Advances in the Treatment of Relapsed/Refractory Myeloma

AFP as a Prognostic and Predictive Marker in HCC 

Targeted Therapies in Advanced NSCLC

Next-Generation Agents for ALK-Positive NSCLC

Advances in Treatment for ALK-Positive NSCLC

The Emerging Role of FLT3 Inhibitors in AML and ASM

Global Perspectives: FLT3 Inhibitors for AML

Acute Promyelocytic Leukemia (APL):  Diagnosis and Treatment

Integrating Novel Therapies into Treatment of B-Cell Malignancies

Extended Adjuvant Endocrine Therapy: The Role of Genomic Profiling

Expert Perspectives on Hereditary Testing in Breast Cancer

Targeting Angiogenesis with Chemotherapy for Advanced Breast Cancer

Importance of Biomarker Testing for RET in Non Small Cell Lung Cancer

Evolution of Predictive Biomarkers for Metastatic CRC

Expert Review on the Multidisciplinary Management of Bladder Cancer

Key Considerations for Detecting and Targeting BRAF Mutations

Advances in Targeted Therapy for Breast Cancer Treatment

Case-Based Insights on Multiple Myeloma

CDK4/6 Inhibitors for Hormone-Driven Breast Cancer

The Emerging Role of Chemotherapy in Metastatic Prostate Cancer

Managing Chemotherapy Toxicity for 5-FU and Capecitabine

Modern-Day Treatment of Chemotherapy-Induced Nausea and Vomiting

2015 Update on Chronic Lymphocytic Leukemia

Treatment Updates in Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia: Refining the Use of BCR-ABL TKIs

Guiding Patients With Colorectal Cancer Along Their Care Journey

Molecular Testing for Advanced Colorectal Cancer

Impact of Upcoming Daratumumab Subcutaneous Formulation for Treatment of Multiple Myeloma

Rash Management

Expert Perspectives on Advanced Pancreatic Ductal Adenocarcinoma

Early Diagnosis of Myeloma: Guideline Compliant Testing 

Identifying EGFR Mutations in NSCLC and Optimizing Therapy

Molecular Testing and EGFR-Mutant Non-Small Cell Lung Cancer

Emerging Approaches: Pancreatic Cancer Systemic Therapy

Treatment Evolution in Metastatic Breast Cancer

Evolving Treatment Landscape of BTK Inhibitors in B-Cell Malignancies

Expanding Targets in NSCLC

Frontline Therapy In Follicular Lymphoma

The Evolving Landscape of Therapy for Follicular Lymphoma

New Treatment Strategies for Follicular Lymphoma

Treatment of Follicular Lymphoma

Practical Perspectives on Treatment of Advanced Gastric/GEJ Cancers

Novel Treatment Approaches in Glioblastoma

Pinpointing Primary Tumor Type and Mutations Improves Outcomes

Advanced Gastrointestinal Stromal Tumors: Historical Perspective, Future Directions

Multidisciplinary Care in Glioblastoma

Global Perspective: CDK4/6 Inhibitors in HR+ Breast Cancer

Global Expert Perspectives: Relapsed/Refractory Multiple Myeloma

Treating Beyond the First Line in HCC

Navigating the Complexities of HCC

New Treatment Strategies for Hepatocellular Carcinoma

Emerging Therapies in HER 2-Positive  Metastatic Breast Cancer

Checkpoint Inhibitors in Head and Neck Cancer

The Era of Immunotherapy for Advanced Head & Neck Cancer Squamous Cell Carcinoma

Treatment of Advanced Head & Neck Squamous Cell Carcinoma

Clinical Advances in HPV-Positive Head and Neck Cancer

Management of Immune Thrombocytopenia

The Evolving Landscape of Immunotherapy for NSCLC

Advancing Role of Immunotherapy in Multiple Myeloma

Initial Therapy for Advanced Renal Cell Carcinoma 

Inside the Clinic: Interdisciplinary Care for Stage IV NSCLC

Georgetown University's Approach to Treating Advanced Colorectal Cancer

Future Strategies in Kidney Cancer Treatment

Liquid Biopsy Use in Metastatic Non-Small Cell Lung Cancer

Addressing Unmet Needs in Liver Cancer

Evolving Approaches for Controlling Liver Metastases in CRC

Treatment Strategies in NSCLC

Treatment Approaches in Non-Driver Lung Adenocarcinoma

Management of Tumor Lysis Syndrome

Videos

Jessica K. Altman, MD, and Naval G. Daver, MD, share their approaches to genetic testing for FLT3 and other actionable mutations in acute myeloid leukemia (AML).

Hematologic Oncology

Overview of FLT3-mutated AML

Insight regarding the assessment of the prevalence of FLT3-ITD versus FLT3-TKD mutations and allelic burden in newly diagnosed acute myeloid leukemia.

Prognostic Impact of FLT3 Mutations in AML

Drs Joshua M. Bauml and Lyudmila A. Bazhenova describe what is understood regarding the behavior of MET exon 14 skipping mutations in non–small cell lung cancer and remark on their prevalence among specific patient populations.

Lung Cancer

MET Exon 14 Skipping Mutations in NSCLC

Drs Joshua M. Bauml and Benjamin Levy react to the development of novel therapies that specifically target MET exon 14 skipping mutations in non–small cell lung cancer.

Advances in Targeting MET Exon 14 Skipping Mutations in NSCLC

Recommendations for using next-generations sequencing panels as well as liquid biopsies to help identify MET exon 14 skipping mutations and other oncogenic drivers in patients with non–small cell lung cancer.

Testing to Identify MET Exon 14 Mutations in NSCLC 

Discussion on the FDA approval of capmatinib, a MET inhibitor, as treatment for patients with MET exon 14-mutated or MET-amplified non–small cell lung cancer based on data demonstrated by the GEOMETRY mono-1 study.

Capmatinib for MET Exon 14-Mutated NSCLC

Implications for treating patients with non–small cell lung cancer who harbor MET exon 14 skipping mutations with tepotinib, a MET inhibitor, based on data revealed by the VISION trial.

Tepotinib for MET Exon 14 Skipping Mutations in NSCLC 

The significance of using MET inhibitors to manage patients who have MET exon 14 skipping mutations in non–small cell lung cancer with CNS (central nervous system) involvement. 

CNS Response to MET Inhibition in NSCLC

Insights on the differences between limited-stage and extensive-stage small-cell lung cancer and recent progress made with combination chemotherapy plus immunotherapy.

Staging for Small-Cell Lung Cancer

Experts in thoracic oncology review data from the IMpower133 and CASPIAN trials as well as the use of chemotherapy with PD-L1 inhibitors for treatment-naïve ES-SCLC in clinical practice. 

Standard of Care for ES-SCLC

Stephen V. Liu, MD, and Jared Weiss, MD, share their thoughts on the impact of the recent approval of trilaciclib prior to platinum/etoposide-based chemotherapy for the treatment of ES-SCLC.

Using Trilaciclib for Treatment of ES-SCLC

Considerations for second-line treatment regimens, the role of immunotherapy in the relapsed/refractory setting, and using lurbinectedin for the management of ES-SCLC.

Management of ES-SCLC: Second Line and Beyond

Jared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.

Emerging Agents and Future of Small Cell Lung Cancer

Small-Cell Lung Cancer